Applied DNA Sciences Announces Completion of First Contract with Dr. Suwelack Skin and Healthcare AG and Appointment of Dr. Stephane Shu Kin So

Jul 25, 2006, 01:00 ET from Applied DNA Sciences, Inc.

    STONY BROOK, N.Y., July 25 /PRNewswire-FirstCall/ -- Applied DNA
 Sciences, Inc. (OTC Bulletin Board:   APDN), a DNA security solutions
 company, announced today the completion of its first contract with Dr.
 Suwelack Skin & Healthcare AG ("Suwelack"). Suwelack is recognized in
 Germany as the leader in the innovation, development and manufacture of
 biomatrices for cosmeceutical and healthcare applications.
     On May 9, 2006, Suwelack adopted APDN's SigNature(TM) Program as one of
 many new initiatives that complement its expansion into the North American
 market. APDN's SigNature(TM) logo was printed with ink containing APDN's
 encrypted botanical DNA technology, onto Suwelack's annual supply of
 packaging and labels.
     Dr. James A. Hayward, CEO of APDN, stated: "We believe that the
 completion of our first contract to supply DNA embedded packaging and
 labels for Suwelack is a strong indication that our DNA technology is
 ready-to-implement. The Suwelack project took less than 3 months from start
 to finish, including negotiations, design, technical specification, DNA
 embedment, printing and authentication validations."
     APDN's forensic-based technology can also help to enhance the power of
 existing security technologies such as barcoding, RFIDs, smart cards, and
 optical memory-based ID systems without adding significant cost or change
 to operations and finished goods.
     APDN also today announced that Dr. Stephane Shu Kin So has joined the
 scientific team at the APDN laboratories in Stony Brook. Dr. Shu Kin So
 received his Ph.D. in Molecular Genetics and Microbiology from State
 University of New York in Stony Brook and has considerable experience in
 molecular biology techniques, DNA cloning and genetic manipulations in
 bacteria. He also received his Bachelor of Science Degree in Biology from
 Binghamton University in Binghamton, New York.
     Dr. Benjamin Liang, Strategic Technology Development Officer, stated:
 "The addition of Dr. Shu Kin So is critical to our authentication
 operations which are now fully functional. Our team provides services to
 governments and corporations, and continues to refine and shorten forensic
 authentication processes."
     About Applied DNA Sciences, Inc.
     Applied DNA Sciences, Inc. (APDN) develops proprietary DNA-embedded
 security solutions that use plant DNA to verify authenticity and protect
 corporate and government agencies from counterfeiting, fraud, piracy,
 product diversion, identity theft and unauthorized intrusion into physical
 plant and databases. Our common stock is registered under Section 12(g) of
 the Securities Exchange Act of 1934 and is listed on the Over-The-Counter
 Bulletin Board under the symbol "APDN". Contact: MeiLin Wan, Applied DNA
 Sciences, Inc., 25 Health Sciences Drive, Stony Brook, New York 11790; Tel:
 631-444- 6370; Fax: 631-444.8848
     About Dr. Suwelack Skin & Healthcare AG
     Dr. Suwelack Skin & Healthcare AG manufactures biomatrices for skin and
 healthcare for cosmeceutical and medical applications. Suwelack's patented
 technology uses a freeze-drying process to gently extract water from
 natural raw materials, as a result of which the raw materials are preserved
 in a highly pure form. By using this technique the company is able to avoid
 using preservative agents, chemical cross-linking agents and perfumes and
 ensure the basis for skin compatibility. Contact: Nikolaus Uleer, Dr.
 Suwelack Skin & Healthcare AG, Josef-Suwelack-Strasse, 48727 Billerbeck,
 Germany Tel: +49-2543-72-247 Fax: +49-2543-72-365
     The statements made by Applied DNA Sciences, Inc. may be
 forward-looking in nature and are made pursuant to the safe harbor
 provisions of the Private Securities Litigation Reform Act of 1995.
 Forward-looking statements describe the Company's future plans,
 projections, strategies and expectations, and are based on assumptions and
 involve a number of risks and uncertainties, many of which are beyond the
 control of Applied DNA Sciences, Inc. Actual results could differ
 materially from those projected due to changes in interest rates, market
 competition, changes in the local and national economies, and various other
 factors detailed from time to time in Applied DNA Sciences' SEC reports and
 filings, including our Form 10-KSB, filed on January 12, 2006, our
 subsequent Quarterly Reports on Form 10-QSB, and our Current Reports on
 Form 8-K . The Company undertakes no obligation to update publicly any
 forward- looking statements to reflect new information, events or
 circumstances after the date hereof to reflect the occurrence of
 unanticipated events.

SOURCE Applied DNA Sciences, Inc.